{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:07:23Z","timestamp":1783058843803,"version":"3.54.6"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biliary tract cancers (BTCs) are a diverse group of malignancies with varied genetic backgrounds. The prevalence of intrahepatic cholangiocarcinoma (iCC) is increasing, particularly in Western countries. Despite advancements in treatments, the prognosis for BTC remains poor. Recent molecular profiling has revealed that up to 40% of iCC cases have targetable genetic alterations. MET amplification, although rare, presents a significant target for therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Presentation<\/jats:title>\n                  <jats:p>A 25-year-old female with a history of ulcerative colitis presented with shoulder pain and a positron emission tomography\u2013computed tomography (PET\u2013CT) scan revealed an enlarged liver and multiple metastases. Histopathological analysis diagnosed poorly differentiated adenocarcinoma. First-line therapy with Cisplatin, Gemcitabine, and Durvalumab resulted in disease progression. Molecular profiling identified a TP53 mutation and MET amplification. Based on these findings, Tepotinib was initiated. Tepotinib treatment led to a significant reduction in tumor size and normalization of CA 19-9 levels within 2 months, achieving a complete metabolic remission lasting up to 17 months. The treatment was well tolerated with minimal side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>MET-amplified BTCs are exceedingly rare, and evidence for targeted treatment is limited. This case demonstrates the efficacy of Tepotinib in a young patient with MET-amplified iCC, showing a long-term response and suggesting a potential new standard treatment option for this molecularly defined entity. This case also highlights the aggressive nature of MET-amplified tumors and the need for targeted second-line therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tepotinib showed remarkable efficacy in treating MET-amplified intrahepatic cholangiocarcinoma, underscoring the importance of molecular profiling in BTCs and suggesting a potential new therapeutic approach for this rare cancer subtype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae265","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T14:04:58Z","timestamp":1727877898000},"page":"1090-1094","source":"Crossref","is-referenced-by-count":7,"title":["Exceptional sustained long-term complete response to Tepotinib in a <i>MET<\/i>-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine"],"prefix":"10.1093","volume":"29","author":[{"given":"Andreas","family":"Reichinger","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz - Barmherzige Schwestern Site , Seilerstaette 4, 4020 Linz,","place":["Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz , Altenberger Strasse 69, 4040 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Essl","sequence":"additional","affiliation":[{"name":"Medical Faculty, Johannes Kepler University Linz , Altenberger Strasse 69, 4040 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kerschner","sequence":"additional","affiliation":[{"name":"Medical Faculty, Johannes Kepler University Linz , Altenberger Strasse 69, 4040 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Burghofer","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz - Barmherzige Schwestern Site , Seilerstaette 4, 4020 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Webersinke","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz - Barmherzige Schwestern Site , Seilerstaette 4, 4020 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz - Barmherzige Schwestern Site , Seilerstaette 4, 4020 Linz,","place":["Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz , Altenberger Strasse 69, 4040 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4813-4435","authenticated-orcid":false,"given":"Bernhard","family":"Doleschal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz - Barmherzige Schwestern Site , Seilerstaette 4, 4020 Linz,","place":["Austria"]},{"name":"Medical Faculty, Johannes Kepler University Linz , Altenberger Strasse 69, 4040 Linz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"2024121021063290800_CIT0001","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2024121021063290800_CIT0002","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"2024121021063290800_CIT0003","first-page":"EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM E\u0301vid"},{"key":"2024121021063290800_CIT0004","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2024121021063290800_CIT0005","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.ccr-21-2384","article-title":"ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024121021063290800_CIT0006","doi-asserted-by":"publisher","first-page":"15421","DOI":"10.1038\/s41598-023-42083-4","article-title":"Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment","volume":"13","author":"Doleschal","year":"2023","journal-title":"Sci Rep"},{"key":"2024121021063290800_CIT0007","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11523-023-00985-3","article-title":"A retrospective analysis of biliary tract cancer patients presented to the molecular tumor board at the comprehensive cancer center Munich","volume":"18","author":"Zhang","year":"2023","journal-title":"Target Oncol"},{"key":"2024121021063290800_CIT0008","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non\u2013small-cell lung cancer with MET Exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"2024121021063290800_CIT0009","doi-asserted-by":"publisher","first-page":"e2200594","DOI":"10.1200\/PO.22.00594","article-title":"The Cholangiocarcinoma in the Young (CITY) study: tumor biology, treatment patterns, and survival outcomes in adolescent young adults with cholangiocarcinoma","volume":"7","author":"Pappas","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2024121021063290800_CIT0010","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/oncolo\/oyac194","article-title":"Response to Capmatinib in a MET fusion-positive Cholangiocarcinoma","volume":"28","author":"Turpin","year":"2023","journal-title":"Oncologist"},{"key":"2024121021063290800_CIT0011","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/15384047.2022.2029128","article-title":"Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature","volume":"23","author":"Lefler","year":"2022","journal-title":"Cancer Biol Ther"},{"key":"2024121021063290800_CIT0012","doi-asserted-by":"publisher","first-page":"1254026","DOI":"10.3389\/fonc.2023.1254026","article-title":"Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"2024121021063290800_CIT0013","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13691-023-00643-5","article-title":"Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification","volume":"13","author":"Yamamura","year":"2024","journal-title":"Int Cancer Conf J"},{"key":"2024121021063290800_CIT0014","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1634\/theoncologist.2020-0535","article-title":"Identification of a Novel EHBP1-MET fusion in an intrahepatic cholangiocarcinoma responding to crizotinib","volume":"25","author":"Yu","year":"2020","journal-title":"The Oncologist"},{"key":"2024121021063290800_CIT0015","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1078-0432.ccr-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC Harboring MET Exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024121021063290800_CIT0016","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-19-2860","article-title":"First-in-man phase I Trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024121021063290800_CIT0017","doi-asserted-by":"crossref","first-page":"101280","DOI":"10.1016\/j.xcrm.2023.101280","article-title":"Tepotinib in patients with non","volume":"4","author":"Le","year":"2023","journal-title":"Cell Rep Med"},{"key":"2024121021063290800_CIT0018","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/12\/1090\/60952611\/oyae265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/12\/1090\/60952611\/oyae265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:49:10Z","timestamp":1733867350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/12\/1090\/7804702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,10,2]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae265","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,2]]}}}